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Summary Epilepsy remains difﬁcult to treat with more than 30% of patients be-
ing refractory to conventional anticonvulsant therapy. Combination therapy may im-
prove seizure control in some of these patients. Tiagabine is a new anticonvulsant
that has a unique mechanism of action as a selective -aminobutyric acid (GABA)
re-uptake inhibitor (SGRI). Twenty consecutive patients with refractory epilepsy were
treated with tiagabine, and prior to tiagabine administration the mean number of
anticonvulsants that each patient had taken was ﬁve. Tiagabine therapy was initi-
ated at a dose of 5 or 10mg per day and was increased at weekly increments of
5 or 10mg per day, respectively. Thirty-ﬁve percent of patients receiving tiagabine
(20—40mg per day, mean 34.29mg per day) achieved a ≥50% reduction in seizure
frequency. Tiagabine was effective when added to carbamazepine, lamotrigine, or
oxcarbazepine. Tiagabine appeared more effective at higher doses. Side effects were
predominately central nervous system-related, the most common being dizziness. For
optimal results, tiagabine should be initiated at low doses and titrated slowly. This
observational study has demonstrated tiagabine to be effective and safe in patients
with refractory epilepsy.
© 2003 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
Introduction
Around 30% of patients with epilepsy have seizures
refractory to conventional anticonvulsant therapy.1
Refractory epilepsy is extremely difﬁcult to treat
andmay be associated with increasedmorbidity, so-
cial isolation, unemployment, and overall reduced
quality of life.2 It may also place a signiﬁcant bur-
den on health care services.
Combination therapy with new anticonvul-
sants can improve seizure control by ≥50% in
around 30% of patients with refractory epilepsy.3
Among the new anticonvulsants, tiagabine has a
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unique mechanism of action, acting as a selective
-aminobutyric acid (GABA) re-uptake inhibitor
(SGRI). Tiagabine is recommended as adjuvant
therapy in adults and children over 12 years
with refractory partial seizures, with or without
secondary generalisation. An integrated analysis
of ﬁve multicentre, double-blind, randomised,
placebo-controlled studies showed that approxi-
mately 25% of patients achieved a ≥50% reduc-
tion in refractory partial seizures after addition of
tiagabine to their existing drug therapy.4 In clinical
trials involving over 3000 patients with epilepsy,
tiagabine demonstrated good, predictable toler-
ability, which was maintained during long-term
therapy.5 Importantly, tiagabine does not affect
serum concentrations of drugs, including other
anticonvulsants, and does not have any clinically
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relevant effects on hepatic metabolism,1 which
simpliﬁes its management as adjunctive therapy.
The Middlesborough General Hospital has a spe-
cialist epilepsy clinic, staffed by a consultant, a
clinical assistant and an epilepsy specialist nurse,
and treats approximately 40 patients per week.
Here we report our experiences with tiagabine as
adjuvant therapy in patients with refractory partial
seizures.
Methods
Twenty consecutive patients with refractory partial
epilepsy were treated with tiagabine between Jan-
uary and December 2000. Tiagabine therapy was
initiated at a dose of 5 or 10mg per day, and in-
creased by either 5 or 10mg per week, respectively,
until maintenance doses were achieved. Patients
received tiagabine two or, when the dose exceeded
30mg, three times daily. All patients received at
least one concomitant anticonvulsant, the dosage
of which remained consistent throughout the treat-
ment period.
Seizure frequency was used to evaluate the ef-
fects of tiagabine therapy, with response deﬁned as
a 50% reduction in seizure frequency compared with
historical baseline (based on a retrospective review
of seizure frequency charts recorded prospectively
by the patient). Adverse effects were monitored
and recorded.
Results
The majority of patients (85%) treated with
tiagabine had refractory complex partial seizures
with or without secondary generalisation (Table 1).
The duration of their epilepsy ranged between 3
and 54 years, and prior to treatment with tiagabine
the mean number of anticonvulsants that each pa-
tient had ever taken was ﬁve (range 3—9). Previous
anticonvulsant therapies included: carbamazepine,
valproate, lamotrigine, gabapentin, topiramate,
oxcarbazepine, and phenytoin. Ten patients were
initiated on tiagabine therapy at a dose of 5mg
per day and 10 patients were initiated at a dose
of 10mg per day. Patients received concomitantly
at least one of the following anticonvulsants: car-
bamazepine, lamotrigine, valproate, phenytoin, or
oxcarbazepine.
Thirty-ﬁve percent of patients who received
tiagabine achieved a ≥50% reduction in seizure
frequency compared to baseline (Figure 1). Main-
tenance doses ranged between 20 and 40mg per
Table 1 Patients’ demographics and epilepsy
details.
Age Range 21—56 years
Sex
Male 10
Female 10
Seizure type
Complex partial 3
Complex partial seizures
with secondary
generalisation
17
Previous medication
9 AEDs 1
8 AEDs 1
7 AEDs 3
6 AEDs 4
4 AEDs 6
3 AEDs 5
day (mean 34.29mg per day), with the majority
of patients receiving 40mg per day. One patient
receiving 40mg per day tiagabine in combination
with lamotrigine experienced an 87% reduction in
seizure frequency (from 30 seizures per month to
four seizures per month). Another patient receiving
30mg per day tiagabine in combination with carba-
mazepine experienced a 90% reduction in seizure
frequency (from 10 seizures per month to 1 seizure
per month). Two patients initiated at 5mg per day
experienced dizziness during titration; however,
tolerability improved after a few weeks of treat-
ment, and both patients were maintained on 30mg
per day.
Side effects experienced by patients were mostly
central nervous system related and included dizzi-
ness (9 patients), tiredness (5 patients), and ataxia
Figure 1 Patients treated with tiagabine who experi-
enced a≥50% reduction in seizure frequency. CBZ: carba-
mazepine; LTG: lamotrigine; OXC: oxcarbazepine; TGB:
tiagabine; VPA: valproate.
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(1 patient). All side effects resolved upon dosemod-
iﬁcation or withdrawal of tiagabine.
Discussion
Refractory epilepsy is notoriously difﬁcult to treat.
In this study, 35% of patients with refractory par-
tial seizures responded to adjunctive therapy with
tiagabine; a response rate similar to that observed
in randomised controlled trials with tiagabine
and other new anticonvulsants.3 The efﬁcacy of
tiagabine was evidenced most clearly in one pa-
tient who achieved seizure control on tiagabine
when previously they had experienced frequent
(4—20 per day) partial seizures with secondary
generalisation over a twenty-year period despite
treatment with combinations of valproate, carba-
mazepine, phenytoin, phenobarbitone, vigabatrin,
lamotrigine, gabapentin, topiramate, clobazam
and acetazolamide.
Patients responding to tiagabine received main-
tenances doses of 20—40mg per day, which is
consistent with the recommended doses of 15—
30mg per day in patients taking concomitant
non-enzyme-inducing-drugs and 30—45mg per day
in patients taking at least one enzyme-inducing
anticonvulsant. Tiagabine therapy appeared more
efﬁcacious at higher dosages, with around 60% of
the patients receiving 40mg per day achieving a
≥50% reduction in seizures. This result is consistent
with other studies that have reported a signiﬁcant
dose—response relationship with tiagabine.4
Tiagabine appeared well-tolerated, with the ad-
verse events observed being consistent with those
commonly reported. Side effects are often ob-
served during initial titration of tiagabine and are
more common during twice daily dosing than dur-
ing three- or four-times-daily regimens.6 This study
highlights the importance of slow dose titration
with tiagabine, as one patient who experienced
dizziness initially, later achieved seizure control
with tiagabine after following a more gradual titra-
tion schedule.
It has been suggested that tiagabine may be
particularly beneﬁcial to patients that have previ-
ously failed to respond to treatment with sodium
channel blockers, patients with a history of cuta-
neous reactions to other drugs, patients with mild
to moderate epilepsy, patients receiving valproate
or other non-enzyme inducing anticonvulsants, and
patients where it is particularly important to avoid
cognitive impairment.7 In this study, patients re-
ceiving concomitant carbamazepine, lamotrigine
or oxcarbazepine had improved seizure control
with tiagabine.
Conclusions
This observational study of tiagabine in clinical
practice has demonstrated it to be effective and
safe for patients with refractory epilepsy. In combi-
nation with an antiepileptic treatment considered
ineffective, tiagabine reduced the frequency of
seizures by at least 50% in around 1/3 of patients
treated. The efﬁcacy of tiagabine was comparable
to that seen in randomised controlled trials with
tiagabine and other new anticonvulsants. In or-
der to achieve optimal results, tiagabine therapy
should be initiated at a low dose and increased
slowly.
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